亞諾法生技近期推出由 GMP 認證合格的工廠製造出的 20 個免疫組化單株抗體,符合美國體外檢驗試劑(IVD class I)的規範。這些抗體經過免疫組化的應用測試可做為生物標記(biomarkers),用於一般的研究及臨床研究來分析各種組織及疾病。這 20 個抗體的推出不只表示亞諾法的產品已能達到更好的品質,同時也代表了亞諾法跨足到體外檢驗試劑(IVD)市場的第一步。我們將會更盡心盡力製作出更合乎臨床應用的單株抗體,讓您的研究更上一層樓! |
ACTN4 (Human lung adenocarcinoma) |
ANXA5 (Human colon cancer) |
CDH17 (Human colon cancer) |
CLDN1 (Human colon cancer) |
CTH (Human liver) |
EGR1 (Human colon cancer) |
EIF2C2 (Human stomach) |
ENO1 (Human lymphoma) |
FOXC2 (Human lung carcinoma) |
GBA (Human breast cancer) |
HMGB1 (Human colon cancer) |
HSD3B1 (Human placenta) |
PGR (Human breast cancer) |
SALL4 (Human testis) |
SPINK1 (Human prostate cancer) |
STIP1 (Human ovarian cancer) |
TARDBP (Human pancreas) |
TFF3 (Human colon cancer) |
TUBA1B (Human breast cancer) |
YAP1 (Human ovary cancer) |
沒有留言:
張貼留言